rs144023803
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_000094.4(COL7A1):c.1732C>T(p.Arg578Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.000116 in 1,613,898 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00013 ( 0 hom. )
Consequence
COL7A1
NM_000094.4 stop_gained
NM_000094.4 stop_gained
Scores
4
2
1
Clinical Significance
Conservation
PhyloP100: 5.33
Genes affected
COL7A1 (HGNC:2214): (collagen type VII alpha 1 chain) This gene encodes the alpha chain of type VII collagen. The type VII collagen fibril, composed of three identical alpha collagen chains, is restricted to the basement zone beneath stratified squamous epithelia. It functions as an anchoring fibril between the external epithelia and the underlying stroma. Mutations in this gene are associated with all forms of dystrophic epidermolysis bullosa. In the absence of mutations, however, an acquired form of this disease can result from an autoimmune response made to type VII collagen. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PP5
Variant 3-48590721-G-A is Pathogenic according to our data. Variant chr3-48590721-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 372330.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr3-48590721-G-A is described in Lovd as [Pathogenic]. Variant chr3-48590721-G-A is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL7A1 | NM_000094.4 | c.1732C>T | p.Arg578Ter | stop_gained | 14/119 | ENST00000681320.1 | NP_000085.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL7A1 | ENST00000681320.1 | c.1732C>T | p.Arg578Ter | stop_gained | 14/119 | NM_000094.4 | ENSP00000506558 | P1 | ||
COL7A1 | ENST00000328333.12 | c.1732C>T | p.Arg578Ter | stop_gained | 13/118 | 1 | ENSP00000332371 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152182Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152182
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000358 AC: 9AN: 251302Hom.: 0 AF XY: 0.0000294 AC XY: 4AN XY: 135848
GnomAD3 exomes
AF:
AC:
9
AN:
251302
Hom.:
AF XY:
AC XY:
4
AN XY:
135848
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000127 AC: 185AN: 1461716Hom.: 0 Cov.: 34 AF XY: 0.000136 AC XY: 99AN XY: 727162
GnomAD4 exome
AF:
AC:
185
AN:
1461716
Hom.:
Cov.:
34
AF XY:
AC XY:
99
AN XY:
727162
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152182Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74336
GnomAD4 genome
AF:
AC:
3
AN:
152182
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74336
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
1
ALSPAC
AF:
AC:
0
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
6
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Recessive dystrophic epidermolysis bullosa Pathogenic:3
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Aug 30, 2017 | The NM_000094.3(COL7A1):c.1732C>T heterozygous nonsense variant was identified in exon 13 of COL7A1. This nonsense variant creates a stop codon at amino acid position 578, NP_000085.1(COL7A1):p.(Arg578*). This is predicted to result in loss of protein function either through truncation (~75% of the protein, including multiple triple helix repeats) or nonsense-mediated decay. This variant is present in the gnomAD population database at a frequency of 0.004%. It has been previously reported in multiple families with recessive dystrophic epidermolysis bullosa in homozygous or compound heterozygous state (Dunnill et al., (1994), Whittock et al., (1999) and Kern et al., (2006)). In addition, other truncating variants downstream of c.1732C>T in the COL7A1 gene have been reported as pathogenic in individuals with this condition (ClinVar). Based on current information and in association with the NM_000094.3(COL7A1):c.3265C>T nonsense variant, this variant has been classified as PATHOGENIC. - |
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The stop gained c.1732C>T p.Arg578Ter variant in COL7A1 gene has been previously reported in homozygous, heterozygous and compound heterozygous states in multiple individuals affected with Epidermolysis bullosa dystrophica Whittock et al., 1999; Alamani et al., 2010; Serafi et al., 2015. The p.Arg578Ter variant has been reported to segregated with disease Serafi et al., 2015. The p.Arg578Ter variant is reported with allele frequency of 0.03% in gnomAD Exomes and is novel not in any individuals in 1000 Genomes. This variant has been reported to the ClinVar database as Pathogenic multiple submissions. The nucleotide change c.1732C>T in COL7A1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. This sequence change creates a premature translational stop signal p.Arg578Ter in the COL7A1 gene. This variant is predicted to cause loss of normal protein function through protein truncation. Loss of function variants in COL7A1 gene have been previously reported to be pathogenic Varki et al., 2007. For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | This sequence change creates a premature translational stop signal (p.Arg578*) in the COL7A1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in COL7A1 are known to be pathogenic (PMID: 16971478). This variant is present in population databases (rs144023803, gnomAD 0.009%). This premature translational stop signal has been observed in individual(s) with autosomal recessive dystrophic epidermolysis bullosa (PMID: 17425959, 26102279). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 372330). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 25, 2021 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 21448560, 28549954, 25525159, 26102279, 7833933, 10504458, 14727126, 28168442, 20357813, 28691931, 29625052, 26689913, 33274474) - |
Epidermolysis bullosa dystrophica Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Aug 22, 2018 | The COL7A1 c.1732C>T (p.Arg578Ter) variant is a stop-gained variant that is predicted to result in a premature termination of the protein. Across a selection of the available literature, The p.Arg578Ter variant has been found in at least 21 individuals with dystrophic epidermolysis bullosa, including in four in a homozygous state, in at least 15 in a compound heterozygous state, and in at least two in a heterozygous state (Dunnill et al. 1994; Hovnanian et al. 1997; Mellerio et al. 1997; Whittock et al. 1999; Almaani et al. 2010; Nagy et al. 2011; Petrof et al. 2013; Takeichi et al. 2015; Serafi et al. 2015; Georgiadis et al. 2016). Three of the studies demonstrated that the p.Arg578Ter variant segregated with disease (Dunnill et al. 1994; Mellerio et al. 1997; Serafi et al. 2015). The p.Arg578Ter variant was absent from 180 control chromosomes and is reported at a frequency of 0.000089 in the Latino population of the Genome Aggregation Database. The p.Arg578Ter variant is predicted to result in premature termination and the loss of approximately 80% of the protein. Due to the potential impact of stop-gained variants and available evidence, the p.Arg578Ter variant is classified as pathogenic for dystrophic epidermolysis bullosa. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Recessive dystrophic epidermolysis bullosa;C0268371:Dominant dystrophic epidermolysis bullosa with absence of skin;C0432321:Pretibial dystrophic epidermolysis bullosa;C0432322:Generalized dominant dystrophic epidermolysis bullosa;C1275114:Epidermolysis bullosa pruriginosa;C1843761:Nonsyndromic congenital nail disorder 8;C1851573:Transient bullous dermolysis of the newborn Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 26, 2022 | - - |
See cases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University Hospital Muenster | Dec 08, 2021 | ACMG categories: PVS1,PM2,PP3,PP5 - |
COL7A1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 11, 2024 | The COL7A1 c.1732C>T variant is predicted to result in premature protein termination (p.Arg578*). This variant has been previously reported in the homozygous or compound heterozygous state in individuals with epidermolysis bullosa dystrophica (Dang et al. 2007. PubMed ID: 17425959; Table SII, Almaani et al. 2011. PubMed ID: 21448560; Serafi et al. 2015. PubMed ID: 26102279; Table S6, Rossi et al. 2021. PubMed ID: 33274474). This variant is reported in 0.0087% of alleles in individuals of Latino descent in gnomAD. Nonsense variants in COL7A1 are expected to be pathogenic. This variant is interpreted as pathogenic. - |
Generalized dominant dystrophic epidermolysis bullosa Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Uncertain
D
MutationTaster
Benign
A;A
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at